Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

Merck's fortunes hinge on success of diabetes drug

Article Abstract:

Merck KGaA is planning a restructuring of its main chemicals and laboratory operations. However, the company's future is dependent on the success of its Glucophage diabetes drug.

Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
Switzerland, Antidiabetic Preparations, Product information, Hypoglycemic agents, Merck KGAA, Glucophage (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Germany's Altana may sell drug division for $7 billion

Article Abstract:

Altana Industrie-Aktien und Anlagen AG of Germany is planning to sell its pharmaceutical company for approximately $7 billion, according to people close to the business. However, public relations person Steffen Mueller would not comment on the alleged plan. Publicly, the chemical company has said it's goal is to strengthen the pharmaceutical unit through consolidations or product licensing and has approximately 1 billion Euros for this purpose.

Author: Whalen, Jeanne, Singer, Jason
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2005
Management dynamics, Parent-to-subsidiary activities, Subsidiary-to-parent activities, Company acquisition/merger, Company Profile, Company business management, Pesticides industry, Herbicides, Altana Industrie-Aktien und Anlagen AG, Sulphur industry, Subsidiaries, divisions and units

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Investors interested in Hoechst consider the effects of merger

Article Abstract:

Article about how investors interested in Hoechst AG shares during the next couple of weeks will have to consider the effects of the pharmaceutical firm's merger with Rhone-Poulenc SA. The merger would create Aventis SA, one of the biggest life science businesses in the world.

Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
Asset sales & divestitures, France, Securities issued, listed, Stockholder data, Pharmaceutical Preparations, Drugs, Brief Article, Rhone-Poulenc S.A., Hoechst AG, Aventis SA

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Germany, Pharmaceutical industry, Chemicals, Chemical industry, Mergers, acquisitions and divestments
Similar abstracts:
  • Abstracts: Ford interested in Daewoo; U.S. concern hasn't voiced a Korea strategy. General Motors turns a corner
  • Abstracts: UAL incurs $1.16 billion net loss amid effects of September attacks. Comair to reduce operations further
  • Abstracts: Deutsche Post's net is expected to decline on higher tax charges. Deutsche Post gains in choppy first day
  • Abstracts: Zone for new kind of Drill? Both sides of strait review oil joint venture. Taiwan, China state firms near pact to be partners on oil
  • Abstracts: Telewest to buy NTL's 50% stake in Cable London for 647.7 million euros. Canal Plus has NC Numericable all to itself
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.